Anocca: Funding, Investors & Team (Sep 2026)
Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity. Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.
Anocca has raised $120M across 3 funding rounds on record, the most recent an undisclosed round of $46.1M announced in Aug 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Anocca Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Anocca Funding Rounds
Anocca raised $47.0M in a Series B announced in Jul 2021.
1.4 years later, an undisclosed round of $26.6M was announced in Dec 2022.
2.7 years later, an undisclosed round of $46.1M was announced in Aug 2025.
Anocca Founders and Leadership Team
Contact details for the Anocca team: 1 of 1 has an email address on file.
Start 14-day free trial →Anocca Funding Compared to Other Biotechnology Startups
Anocca's latest round of $46.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Anocca in Biotechnology and Södertälje
Companies Similar to Anocca
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Anocca Funding FAQs
What does Anocca do?
Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity. Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.
How much funding has Anocca raised?
Anocca has raised $120M across 3 rounds on record. The most recent is an undisclosed round of $46.1M announced in Aug 2025.
When did Anocca last raise funding?
Anocca's most recent funding round on record is an undisclosed round of $46.1M, announced in Aug 2025.
Who is the CEO of Anocca?
Reagan Jarvis is listed as CEO at Anocca.
Where is Anocca headquartered?
Anocca is based in Södertälje, Vasternorrlands Lan, Sweden.
How many employees does Anocca have?
Anocca is in the 51-100 employee band.
How does Anocca's funding compare to other Biotechnology startups?
Anocca's latest round of $46.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Anocca Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Anocca is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.